MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice.
Rodriguez, Amanda Canas
Payen, Valéry L
MetadataShow full item record
Capeloa, T., Krzystyniak, J., Rodriguez, A. C., Payen, V. L., Zampieri, L. X., Pranzini, E., Derouane, F., et al. (2022). MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice.. Cancers (Basel), 14 (6) https://doi.org/10.3390/cancers14061488
In oncology, the occurrence of distant metastases often marks the transition from curative to palliative care. Such outcome is highly predictable for breast cancer patients, even if tumors are detected early, and there is no specific treatment to prevent metastasis. Previous observations indicated that cancer cell mitochondria are bioenergetic sensors of the tumor microenvironment that produce superoxide to promote evasion. Here, we tested whether mitochondria-targeted antioxidant MitoQ is capable to prevent metastasis in the MDA-MB-231 model of triple-negative human breast cancer in mice and in the MMTV-PyMT model of spontaneously metastatic mouse breast cancer. At clinically relevant doses, we report that MitoQ not only prevented metastatic take and dissemination, but also local recurrence after surgery. We further provide in vitro evidence that MitoQ does not interfere with conventional chemotherapies used to treat breast cancer patients. Since MitoQ already successfully passed Phase I safety clinical trials, our preclinical data collectively provide a strong incentive to test this drug for the prevention of cancer dissemination and relapse in clinical trials with breast cancer patients.
breast cancer, cancer relapse, metastasis, mitochondria, mitochondrial superoxide, MitoQ, mitochondria-targeted antioxidant, metastasis prevention, translational research
European Union (FP7/2007-2013 ERC Independent Researcher Starting Grant 243188 TUMETABO, European Union’s Horizon 2020 research innovation program under the Marie Skłodow-ska-Curie grant agreement No 722605 TRANSMIT)
Communauté Française de Belgique (ARC 09/14-020 and ARC 14/19-058)
Belgian Science Policy Office (Interuniversity Attraction Pole (IAP) grant #UP7-03)
Fondation Belge contre le Cancer (Fundamental Research Grants #F86 and #FAF-F/2018/1282, grants FRSM 3.4567.10, FRFC 2.5025.12, CDR J.0135.18, U.G002.19, Grants 7.4508.14 and 7.4529.17, N/A)
Louvain Foundation (N/A)
Fonds Joseph Maisin (N/A)
External DOI: https://doi.org/10.3390/cancers14061488
This record's URL: https://www.repository.cam.ac.uk/handle/1810/337736